Inventor · disambiguated record
Gordon Yiu Kon Ng
Also filed as: NG GORDON · NG GORDON YIU KON
23 granted patents·20 pending applications·280 citations·filing 2004–2024
95Inventor score
Top patents by PatentIndex Score
43 records- 0199US7915391B2Humanized c-Kit antibodyAMGEN INC·Filed 2007·Granted Mar 29, 2011·112 cites·10 claims
- 0297US9499634B2Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cellsZYMEWORKS INC·Filed 2013·Granted Nov 22, 2016·50 cites·30 claims
- 0396US10000576B1Bispecific antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2018·Granted Jun 19, 2018·23 cites·30 claims
- 0495US8791249B2Nucleic acid encoding humanized c-kit antibodyAMGEN INC·Filed 2013·Granted Jul 29, 2014·21 cites·6 claims
- 0594US8436150B2Humanized C-kit antibodyNG GORDON·Filed 2011·Granted May 7, 2013·29 cites·15 claims
- 0691US9388231B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2013·Granted Jul 12, 2016·16 cites·38 claims
- 0790US2025122305A1Bispecific antigen binding constructs targeting her2ZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 0889US11325981B2Bispecific antigen-binding constructs targeting Her2ZYMEWORKS INC·Filed 2018·Granted May 10, 2022·2 cites·19 claims
- 0989US10947319B2Bispecific antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2014·Granted Mar 16, 2021·5 cites·18 claims
- 1087US11147886B2Drug-conjugated bi-specific antigen-binding constructsZYMEWORKS INC·Filed 2016·Granted Oct 19, 2021·3 cites·15 claims
- 1185US9771573B2Methods of quantitating heavy and light chain polypeptide pairsZYMEWORKS INC·Filed 2013·Granted Sep 26, 2017·8 cites·36 claims
- 1284US2024343802A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 1381US12215166B2Bispecific antigen binding constructs targeting HER2ZYMEWORKS BC INC·Filed 2022·Granted Feb 4, 2025·0 cites·23 claims
- 1481US2025084184A1Methods of using bispecific antigen-binding constructs targeting her2ZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 1580US8609655B2Calcimimetic compound for use in the treatment of epithelial injuryGEIBEL JOHN PETER·Filed 2009·Granted Dec 17, 2013·2 cites·5 claims
- 1678US10358479B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2016·Granted Jul 23, 2019·2 cites·24 claims
- 1776US11965036B2Bispecific antigen-binding constructs targeting HER2ZYMEWORKS BC INC·Filed 2021·Granted Apr 23, 2024·0 cites·19 claims
- 1875US10508154B2Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cellsZYMEWORKS INC·Filed 2016·Granted Dec 17, 2019·1 cites·37 claims
- 1973US10273303B2Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereofZYMEWORKS INC·Filed 2014·Granted Apr 30, 2019·2 cites·21 claims
- 2073US10239951B2Bispecific HER2 and HER3 antigen binding constructsZYMEWORKS INC·Filed 2014·Granted Mar 26, 2019·2 cites·20 claims
- 2172US7605120B2Antagonists of the brandykinin B1 receptorAMGEN INC·Filed 2004·Granted Oct 20, 2009·2 cites·11 claims
- 2272US2009048149A1Antagonists of the bradykinin B1 receptorAMGEN INC·Filed 2008·Application pending·0 cites
- 2371US2021317212A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2021·Application pending·0 cites
- 2468US11248037B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2019·Granted Feb 15, 2022·0 cites·36 claims
- 2566US12157775B2Methods of using bispecific antigen-binding constructs targeting HER2ZYMEWORKS BC INC·Filed 2020·Granted Dec 3, 2024·0 cites·23 claims
- 2665US8288351B2Antagonists of the bradykinin B1 receptorNG GORDON·Filed 2008·Granted Oct 16, 2012·0 cites·14 claims
- 2765US8278280B2Antagonists of the bradykinin B1 receptorNG GORDON·Filed 2008·Granted Oct 2, 2012·0 cites·14 claims
- 2861US2021269553A1Methods using monovalent antigen binding constructs targeting her2ZYMEWORKS INC·Filed 2020·Application pending·0 cites
- 2961US2019248897A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2019·Application pending·0 cites
- 3059US2014154253A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2013·Application pending·0 cites
- 3154US2013336973A1Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc DomainZYMEWORKS INC·Filed 2013·Application pending·0 cites
- 3254US2015125449A1Single-Arm Monovalent Antibody Constructs and Uses ThereofZYMEWORKS INC·Filed 2013·Application pending·0 cites
- 3353US2017355779A1Methods of using bispecific antigen-binding constructs targeting her2ZYMEWORKS INC·Filed 2015·Application pending·0 cites
- 3452US2016297891A1Methods using monovalent antigen binding constructs targeting her2ZYMEWORKS INC·Filed 2014·Application pending·0 cites
- 3551US10526411B2Methods and compositions relating to anti-CCR7 antigen binding proteinsAMGEN INC·Filed 2017·Granted Jan 7, 2020·0 cites·5 claims
- 3649US2016031997A1Methods and compositions relating to anti-ccr7 antigen binding proteinsAMGEN INC·Filed 2014·Application pending·0 cites
- 3748US2005130203A1Novel GABAB receptor DNA sequencesUS GOV HEALTH & HUMAN SERV·Filed 2004·Application pending·0 cites
- 3847US2016257763A1Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domainZYMEWORKS INC·Filed 2016·Application pending·0 cites
- 3946US2016355588A1Bispecific CD3 and CD19 Antigen Binding ConstructsZYMEWORKS INC·Filed 2014·Application pending·0 cites
- 4046US2020297862A1Methods of using bispecific antigen-binding constructs targeting her2ZYMEWORKS INC·Filed 2017·Application pending·0 cites
- 4146US2017174783A1Single-Arm Monovalent Antibody Constructs and Uses ThereofZYMEWORKS INC·Filed 2016·Application pending·0 cites
- 4242US2014072581A1Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy ChainsZYMEWORKS INC·Filed 2013·Application pending·0 cites
- 4341US2016326249A1Bi-specific cd3 and cd19 antigen-binding constructsZYMEWORKS INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →